/
We are a clinical-stage biotechnology company focused on unlocking the broad potential of ribonucleic acid ( RNA ) medicines (also known as oligonucleotides), or those targeting RNA, to transform human health. Our RNA medicines platform, PRISM , combines multiple modalities, chemistry innovation and deep insights into human genetics to deliver scientific breakthroughs that treat both r…
The business is unprofitable at the operating level (-504.09% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 60.5% YoY. Margins deteriorated 402.2pp alongside, both lines moving the wrong way.
Negative free cash flow of -$188M. The business is consuming cash, not generating it. Operating margin contracted 402.2pp YoY, cost discipline may be slipping.
Profitability & Returns
Revenue (FY)
$43M
▼ -60.5% YoY
Net Income (TTM)
-$184M
▼ -110.7% YoY
Op. Margin
-504.09%
▼ -402.2pp YoY
ROIC
-45.45%
▲ +12.7pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$185M
▼ -23.9% YoY
Op. Cash Flow (TTM)
-$184M
▼ -24.1% YoY
Net Debt
-$529M
Net Cash Position
Cash & Equiv.
$545M
5Y CAGR: +16.3%
Continue Research